XML 21 R7.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Total
Balance at Mar. 31, 2019 $ 226 $ 65,094 $ 70,428 $ (2,626) $ 133,122
Balance (in shares) at Mar. 31, 2019 22,607,712        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income     15,748   15,748
Cash dividend on common stock     (4,306)   (4,306)
Exercise of stock options $ 1 226     $ 227
Exercise of stock options (in shares) 58,000       58,000
Common stock repurchased $ (2) (1,017)     $ (1,019)
Common stock repurchased (in shares) (204,100)        
Restricted stock grants (in shares) 82,673        
Stock-based compensation expense   346     346
Other comprehensive income (loss), net       4,725 4,725
Balance at Mar. 31, 2020 $ 225 64,649 81,870 2,099 148,843
Balance (in shares) at Mar. 31, 2020 22,544,285        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income     10,472   10,472
Cash dividend on common stock     (4,461)   (4,461)
Exercise of stock options $ 1 49     $ 50
Exercise of stock options (in shares) 20,000       20,000
Common stock repurchased $ (3) (1,444)     $ (1,447)
Common stock repurchased (in shares) (295,900)        
Restricted stock grants (in shares) 90,763        
Restricted stock cancelled (in shares) (7,913)        
Stock-based compensation expense   396     396
Other comprehensive income (loss), net       (2,259) (2,259)
Balance at Mar. 31, 2021 $ 223 63,650 87,881 (160) 151,594
Balance (in shares) at Mar. 31, 2021 22,351,235        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income     21,820   21,820
Cash dividend on common stock     (4,769)   (4,769)
Exercise of stock options   17 (1)   $ 16
Exercise of stock options (in shares) 6,000       6,000
Common stock repurchased $ (2) (1,938)     $ (1,940)
Common stock repurchased (in shares) (278,148)        
Restricted stock grants (in shares) 69,285        
Restricted stock cancelled (in shares) (20,976)        
Stock-based compensation expense   319     319
Other comprehensive income (loss), net       (9,791) (9,791)
Balance at Mar. 31, 2022 $ 221 $ 62,048 $ 104,931 $ (9,951) $ 157,249
Balance (in shares) at Mar. 31, 2022 22,127,396